BIBLIOGRAFÍA

HIPERTROFIA BENIGNA DE PRÓSTATA

Bibliografía Seleccionada


Bibliografía Recomendada

9. Abrams P; Schafer W; Tammela TL; Barrett DM; Hedlund H; Rollema HJ; Matos-Ferreira A; Nordling J; Bruskevitz R; Andersen JT; Hald T; Miller P; Kirby R; Mustonen S; Cannon A; Jacobsen CA; Gormley GJ; Malice MP; Bach MA.: Improvement of


17. Carter A; Sells H; Speakman M; Ewings P; MacDonagh R; O'Boyle P.: A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up. BJU Internat. 1999 Feb. 83(3): 254-9.


21. Chatelain C; Autet W; Brackman F.: Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a
BIBLIOGRAFÍA


39. Hudson PB; Boake R; Trachtenberg J; Romas NA; Rosenblatt S; Narayan P; Geller J; Lieber MM; Elhilali M; Norman R; Patterson L; Perreault JP; Malek GH; Bruskewitz RC; Roy JB; Ko A; Jacobsen CA; Stoner E.: Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology. 1999 Apr. 53 (4):690-5.


88

PROCESO HIPERTROFIA BENIGNA DE PRÓSTATA – CÁNCER DE PRÓSTATA


59. Roehrborn C.G., Boyle P., Bergner D., y cols: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a


Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J.: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J. Urol. 2000 Jan.163(1):13-20.


Schafer W; Tammela TL; Barrett DM; Abrams P; Hedlund H; Rollema HJ; Nordling J; Andersen JT; Hald T; Matos-Ferriera A; Bruskewitz R; Miller P; Mustonen S; Cannon A; Malice MP; Jacobsen CA; Bach MA.: Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Finasteride Urodynamics Study Group. Urology. 1999 Aug. 54(2):278-83.


Singleton WB; Terrell F; Renfroe DL; Kolski JM; Fowler JE Jr A randomized prospective study of laser ablation of the prostate versus transurethral resection of


CÁNCER DE PRÓSTATA

Bibliografía Seleccionada


Bibliografía Recomendada


153. Del Regato JA, Trailins AH, Pittman DD: Twenty years follow-up of patients with inoperable cancer of the prostate (stage C) treated by radiotherapy: report of a


160. Eisenberger MA, Southwest Oncology Group: Phase III Comparison of Flutamide vs Placebo Following Bilateral Orchiectomy in Patients with Stage D2 Adenocarcinoma of the Prostate (Summary Last Modified 12/92), SWOG-8894, clinical trial, closed, 09/15/1994.


165. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.


167. Fair WR, Cookson MS, Stroumbakis N, et al.: Update on neoadjuvant androgen deprivation therapy (ADT) and radical prostatectomy in localized prostate cancer.


349. Thompson IM, Southwest Oncology Group: Phase III Randomized Evaluation of Adjuvant Radiotherapy vs No Adjuvant Therapy Following Radical Prostatectomy and Pelvic Lymphadenectomy in Surgical Stage C Adenocarcinoma of the Prostate (Summary Last Modified 05/98), SWOG-8794, clinical trial, closed, 01/01/1997.


